By Brooke Millman, JD, Vice President, Site Contracts & Budgets, Russell John, Global Director of Grants Management and Institution Benchmarking, and Tia Allison, Global Contracts Manager
As we emerge from crisis-response mode and embark on the path to recovery, we find ourselves—as a world, a country and an industry—in a period of transition and uncertainty.
While much remains unresolved, we do know this: Sites and sponsors will be recalibrating everything, especially budgets for either new components of trials or changes to clinical trials. We anticipate that many site budgets will need to be recalculated, amended and renegotiated. We expect an increase in amendment requests across ongoing studies to modify site budgets beginning now and running through the fall.
At WCG Clintrax, we’ve outlined the 5 critical changes sites and sponsors should be considering to best plan for the future: